June 27, 2017
Minneapolis, Minn., – Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2 trial, the first sham-controlled clinical trial of Targeted … Continued
June 20, 2017
Minneapolis, Minn., – Holaira, a developer of medical devices to treat obstructive lung diseases, today announced that it has changed its name to Nuvaira, effective immediately. In addition, the company … Continued
June 14, 2017
BALTIMORE, MD – Personal Genome Diagnostics Inc. (PGDx) today announced an agreement with the U.S. Department of Veterans Affairs (VA) to provide its PlasmaSELECTTM 64 liquid biopsy profiling assay … Continued
June 05, 2017
Earlens said today it closed a total of $118 million in funding, with $73 million coming from an offering of Series C preferred stock and $45 from a structured debt facility … Continued
June 02, 2017
Personal Genome Diagnostics Inc. (PGDx), a pioneer in cancer genomic testing, today highlighted its patent-pending microsatellite instability (MSI) testing technology following the U.S. Food and Drug Administration’s (FDA) accelerated approval … Continued